<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>298</serviceExecutionTime><Trial id="171986"><TitleDisplay>Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed TIDM</TitleDisplay><TitleOfficial>Fast Track Continuous Subcutaneous Insulin Infusion (CSII) in Children With Newly Diagnosed Type 1 Diabetes Mellitus: An Evaluation of a Novel CSII Device in the Immediate Period Following Diagnosis of Type 1 Diabetes (TIDM)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00476788</Identifier><Identifier type="Organisational Study">X060928006</Identifier></Identifiers><Indications><Indication id="836">Insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Omnipod Insulin Management System</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20524" type="Company"><TargetEntity id="5001998137" type="organizationId">University of Alabama at Birmingham</TargetEntity></SourceEntity><SourceEntity id="836" type="ciIndication"><TargetEntity id="E10" type="ICD10"/><TargetEntity id="10067584" type="MEDDRA"/><TargetEntity id="D003922" type="MeSH"/><TargetEntity id="-686743471" type="omicsDisease"/><TargetEntity id="507" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20524">University of Alabama at Birmingham</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>14</PatientCountEnrollment><DateStart>2007-04-30T00:00:00Z</DateStart><DateEnd type="actual">2009-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-16T16:22:38Z</DateChangeLast><DateAdded>2014-02-11T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Alabama at Birmingham</Affiliation><Name>Elaine C Moreland, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients aged 1 to 10 years of age&lt;/li&gt;&lt;li&gt;Patients present to the Children's Hospital of Alabama with a new diagnosis of type I diabetes&lt;/li&gt;&lt;li&gt;Patients may be admitted to the inpatient unit&lt;/li&gt;&lt;li&gt;From the ER&lt;/li&gt;&lt;li&gt;From an outside facility to Children's Hospital&lt;/li&gt;&lt;li&gt;Seen in our outpatient clinic for the first time having been diagnosed at an outside facility&lt;/li&gt;&lt;li&gt;If patients are recruited from the outside facility in our outpatient clinic, the diagnosis must have been made within 2 weeks of the visit. A total of 20 patients and  20 control subjects will be recruited over a 6-month period&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with diabetes due to other causes (neonatal diabetes, pancreatitis, cystic fibrosis, etc)&lt;/li&gt;&lt;li&gt;Patients will&amp;lt; 2 years of age&lt;/li&gt;&lt;li&gt;Patients &gt; 8 years of age&lt;/li&gt;&lt;li&gt;Lack any presence of other systemic disease(s), such as neoplastic disease or renal failure&lt;/li&gt;&lt;li&gt;Patients must have adequate parental support and stable home environment (eg, children in foster care or with a history of suspected abuse or neglect would be excluded)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean Glycated Hemoglobin (A1c): measure of glycemic control (A1c) over preceding 8 weeks. Normal for a patient between ages 1 and 10 years would be 7.0 to 8.5%</Description><Timeframe>6.9 months (average)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of Reported Adverse Events: adverse events are defined as a change from baseline</Description><Timeframe>6.9 months (average)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate early initiation of continuous subcutaneous insulin infusion (CSII)      therapy in young children using a novel delivery method in the form of a self-contained,      lightweight, and disposable insulin pump unit controlled with a wireless handheld device.       The study anticipates that the initiation of this CSII device in the immediate      post-diagnosis period in this population will result in good glycemic control and greater      parental satisfaction when compared to intensive insulin injection therapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Investigators would recruit 14 pediatric patients, aged 1 to 10 years, from a pool of all children newly diagnosed with T1DM admitted to the Children's Hospital of Alabama to use the pump. General diabetes education and CSII-specific      training would take place in a series of outpatient sessions with the principal investigator  and study nurse.      Patients would be placed on an Omnipod insulin pump within 2 months of diagnosis providing that all requisite      education and training has been successfully completed. Initiation of insulin pump therapy would be within 3 months of the diagnosis of type 1 diabetes mellitus. Data would be collected for both      study group and control group patients for 6 months via phone calls and monthly clinic      visits. Areas which would be evaluated include glycemic control, residual endogenous insulin      secretion, frequency of severe adverse events, parental distress, insulin needs, and      physical growth. While initiating CSII in the immediate post-diagnosis period in this      population may be initially time-intensive, it would be anticipated that it would ultimately become      time-saving because of the greater ease in blood sugar management.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Children's Hospital</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3>35233</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts/></Site><Site><Name>Children s Hospital</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3> 35233</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="7800">Subjects with Newly Diagnosed Type I Diabetes Mellitus</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00476788</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Insulin dependent diabetes" id="18111"><Endpoint>Assessment of HbA1c Levels</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Insulin dependent diabetes" id="18160"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18162">Assessment of adverse effects</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Insulin dependent diabetes" id="35101"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16827">Subjects with Type 1 Diabetes Mellitus</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Insulin dependent diabetes" id="13757"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13758">Subjects with chronic kidney disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13815"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2007-05-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-02-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="286413"><TitleDisplay>Effects of PRVC modality on respiratory dynamics, hemodynamics and oxygenation in elderly patients undergoing laparoscopic gastrointestinal surgery</TitleDisplay><TitleOfficial>Effects of PRVC modality on respiratory dynamics, hemodynamics and oxygenation in elderly patients undergoing laparoscopic gastrointestinal surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR-IOR-17010512</Identifier></Identifiers><Indications><Indication id="2979">Surgical procedure</Indication></Indications><BiomarkerNames><BiomarkerName id="44245" role="Therapeutic effect marker" type="Biochemical">Oxygenation index</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>conventional volume control (VC) ventialtion mode</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pressure regulated volume control (PRVC) ventilation mode</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1053948" type="Company"><TargetEntity id="5035560077" type="organizationId">Tumor Hospital of Hebei Province</TargetEntity></SourceEntity><SourceEntity id="2979" type="ciIndication"><TargetEntity id="10042613" type="MEDDRA"/><TargetEntity id="D013514" type="MeSH"/><TargetEntity id="1043" type="siCondition"/><TargetEntity id="1381" type="siCondition"/><TargetEntity id="1045" type="siCondition"/><TargetEntity id="3645" type="siCondition"/><TargetEntity id="1036" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1053948">Hebei Provincial Cancer Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2017-02-01T00:00:00Z</DateStart><DateEnd type="estimated">2017-12-01T00:00:00Z</DateEnd><DateChangeLast>2017-02-01T04:44:46Z</DateChangeLast><DateAdded>2017-02-02T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>The Fourth Hospital of Hebei Medical University</Affiliation><Email>346338504@qq.com</Email><Name>haoliying</Name><Phone>+86 13739703545</Phone></Contact><Contact type="Public contact"><Email>xuhongmeng66@aliyun.com</Email><Name>xuhongmeng</Name><Phone>+86 13603110056</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients undergoing laparoscopic surgery under general anesthesia&lt;/li&gt;&lt;li&gt;Aged 60 to 80 years old, male and female&lt;/li&gt;&lt;li&gt;ASA I to II&lt;/li&gt;&lt;li&gt;No respiratory system disease&lt;/li&gt;&lt;li&gt;Surgery is expected to 2 to 4 h&lt;/li&gt;&lt;li&gt;Liver and kidney function is normal&lt;/li&gt;&lt;li&gt;Signed informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Other clinical trials were conducted within the first 4 weeks of the study&lt;/li&gt;&lt;li&gt;Respiratory depression, (lung) airway obstruction or tissue hypoxia and other poor lung function&lt;/li&gt;&lt;li&gt;Drug and/or alcohol abuse&lt;/li&gt;&lt;li&gt;Pregnant or lactating women&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Respiratory dynamics</Description><Timeframe>After intubation (T0), outcome, immediately after pneumoperitoneum (T1), 30, 60, 120 min after pneumoperitoneum (T2) and at the end of operation (T5)</Timeframe></Measure><Measure><Description>Hemodynamic parameters</Description><Timeframe>After intubation (T0), outcome, immediately after pneumoperitoneum (T1), 30, 60, 120 min after pneumoperitoneum (T2) and at the end of operation (T5)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Post operative 24 h temperature</Description></Measure><Measure><Description>The hospitalization days</Description></Measure><Measure><Description>Pulmonary complications after operation</Description></Measure><Measure><Description>Secondary endotracheal intubation to ICU</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study is  to investigate the pressure regulated volume control (PRVC) ventilation mode and conventional volume control (VC) ventilation in laparoscopic gastrointestinal surgery in elderly patients with mechanical ventilation airway pressure, oxygenation index, static lung compliance effect of respiratory parameters and hemodynamics, oxygenation, prognosis. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients (n = 50/arm) will be treated either in volume controlled ventilation mode or pressure regulated volume control ventilation mode.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>The Fourth Hospital of Hebei Medical University</Name><Address1>Shijiazhuang</Address1><Address2>Hebei</Address2><CountrySubDivision>Hebei</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gastrointestinal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18219">Subjects with specific disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18739">Subjects Undergoing Surgery</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR-IOR-17010512</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other gastrointestinal disease" id="43401"><Endpoint>Hematological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other gastrointestinal disease" id="43526"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other gastrointestinal disease" id="42921"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="43526"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="43661"><Endpoint>Assessment of Device Related Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Other gastrointestinal disease" id="43681">Requirement for reintubation</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="43662"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Other gastrointestinal disease" id="43663">Assessment of duration of hospitalization</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="43672"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="44054"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other gastrointestinal disease" id="32953"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="32960"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="34319"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="32955">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other gastrointestinal disease" id="35070"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other gastrointestinal disease" id="24021"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24958"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="24372">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other gastrointestinal disease" id="29150"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="24465">Subjects with history of/current alcohol/drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-02-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="311544"><TitleDisplay>Biofilm Modified Macrophage Phenotype and Function in Diabetic Wound Healing</TitleDisplay><TitleOfficial>Biofilm Modified Macrophage Phenotype and Function in Diabetic Wound Healing</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03271580</Identifier><Identifier type="Organisational Study">2017H0010</Identifier></Identifiers><Indications><Indication id="347">Wound healing</Indication><Indication id="790">Diabetic foot ulcer</Indication><Indication id="97">Diabetes mellitus</Indication></Indications><BiomarkerNames><BiomarkerName id="146" role="Therapeutic effect marker" type="Physiological">Ankle-brachial index</BiomarkerName><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="36136" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytokines</BiomarkerName><BiomarkerName id="46507" role="Therapeutic effect marker" type="Cellular">Macrophages</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Ankle brachial index test</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Finger prick test</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Negative Wound Pressure Therapy (NPWT)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Punch biopsy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Vac sponge collection</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20649" type="Company"><TargetEntity id="5000861728" type="organizationId">Ohio State University</TargetEntity></SourceEntity><SourceEntity id="347" type="ciIndication"><TargetEntity id="D014945" type="MeSH"/></SourceEntity><SourceEntity id="790" type="ciIndication"><TargetEntity id="10056340" type="MEDDRA"/><TargetEntity id="D017719" type="MeSH"/><TargetEntity id="-1424289263" type="omicsDisease"/><TargetEntity id="495" type="siCondition"/></SourceEntity><SourceEntity id="97" type="ciIndication"><TargetEntity id="10012601" type="MEDDRA"/><TargetEntity id="D003920" type="MeSH"/><TargetEntity id="-203480060" type="omicsDisease"/><TargetEntity id="506" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="20649">Ohio State University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>28</PatientCountEnrollment><DateStart>2017-02-05T00:00:00Z</DateStart><DateEnd type="estimated">2018-08-01T00:00:00Z</DateEnd><DateChangeLast>2017-09-12T10:17:01Z</DateChangeLast><DateAdded>2017-09-06T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>amy.hoover@osumc.edu</Email><Name>Amy Hoover, LPN</Name><Phone>614-293-0390</Phone></Contact><Contact type="Scientific contact"><Affiliation>Ohio State University</Affiliation><Name>Sashwati Roy, Ph.D</Name></Contact><Contact type="Public contact"><Email>Samir.Zaparde@osumc.edu</Email><Name>Samir Zaparde, MD</Name><Phone>614-313-4921</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 18 to 70 years old&lt;/li&gt;&lt;li&gt;Willing and able to provide informed consent&lt;/li&gt;&lt;li&gt;Willing and able to comply with protocol instructions, including biopsies and study visits&lt;/li&gt;&lt;li&gt;Diabetics with HbA1c&amp;lt;/= 9&lt;/li&gt;&lt;li&gt;Chronic (open &gt;/= 30 days) infected or non-infected foot ulcers Wagner grade 2 to 3&lt;/li&gt;&lt;li&gt;Receiving Negative Wound Pressure Therapy (NPWT)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Revascularization surgery on the target wound within 30 days prior to enrollment&lt;/li&gt;&lt;li&gt;Inadequate arterial supply, as evidenced by any of the following (for wounds below the knee):&lt;ul&gt;&lt;li&gt;TcOM&amp;lt; 30 mmHg&lt;/li&gt;&lt;li&gt;ABI&amp;lt; 0.7 or &amp;gt; 1.3&lt;/li&gt;&lt;li&gt;TBI&amp;lt; 0.6&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subjects with marked immunodeficiency (HIV/AIDS, organ transplant patients and actively being treated for cancer)&lt;/li&gt;&lt;li&gt;Women who are pregnant&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Assess macrophage phenotype and functional modification due to biofilm infection in diabetic patients: wound tissue macrophage will undergo a series of laboratory studies including: flow cytometry, Immunophnotyping, cytokine assays (pg/ml), and ELISA (pg/ml)</Description><Timeframe>One and half year for complete results</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Characterize difference between wound macrophages and macrophages derived from peripheral blood in diabetic patients: mechanism responsible for downregulated wound inflammatory cell function in patients with diabetes.This will be assessed through immunohistochemistry (IHC) and scanning electron microscopy (SEM)</Description><Timeframe>One and half year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim is to study the microenvironment of chronic biofilm infection in diabetic wounds      which shows deregulated immune cells responses and biofilm interaction resulting in      delayed/impaired/non wound healing. Investigators seek to understand immune evasion strategy of biofilms      and study mechanisms which biofilm modify macrophages phenotype and functions in such wounds.&lt;br/&gt;The specific objectives are to:&lt;br/&gt;Determine if functionally active macrophage isolated from biofilm-infected diabetic wounds show extra cellular matrix degrading phenotype causing wound collagen degradation.&lt;br/&gt;Understand by investigating whether increased presence of ECM degrading wound macrophage phenotypes in biofilm infected human diabetic wounds are associated with reduced wound collagen levels and increased wound recurrence. End goal will be to understand the mechanism in which biofilm modulates the wound macrophage phenotype and function.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Diabetic patients with infected ulcers and non-infected ulcers (with HbA1c &amp;lt; 9 with who have wound 4weeks or longer with or without infection) will undergo finger prick test for HbA1c measurement, punch biopsy (wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding [if bleeding Cautery will be used to stop bleeding]), VAC sponge collection (NPWT sponge which will be discarded as biological waste, will be collected for wound macrophage isolation) and ankle brachial index test (blood pressure test). Diabetic patients with chronic foot ulcer(s) that will be receiving Negative Wound Pressure Therapy (NPWT) will be enrolled and observed. A total of 18 patients will be infected and 10 patients will be non-infected serving as the control for the study. The inclusion and exclusion criteria will be carefully selected to enroll diabetic patients who have wound tissue oxygenation adequate to support wound healing.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Comprehsive Wound Care Centers,The Ohio State University Hospital</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43210</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>amy.hoover@osumc.edu</Email><Name>Amy Hoover, LPN</Name><Phone>614-293-0390</Phone></Contact><Contact type="Facility contact backup"><Email>Samir.Zaparde@osumc.edu</Email><Name>Samir Zaparde, MD</Name><Phone>614-313-4921</Phone></Contact><Contact type="Facility investigator"><Name>Sashwati Roy, Ph.D</Name></Contact></Contacts></Site><Site><Name>Davis Heart and Lung Research Institute</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43210</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>sashwati.roy@osumc.edu</Email><Name>Sashwati Roy, Ph.D</Name><Phone>614-906-4612</Phone></Contact><Contact type="Facility contact backup"><Email>amy.hoover@osumc.edu</Email><Name>Amy Hoover, LPN</Name><Phone>6142930390</Phone></Contact><Contact type="Facility investigator"><Name>Sashwati Roy, Ph.D</Name></Contact></Contacts></Site><Site><Name>Martha Morehouse Medical Plaza</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43221</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>amy.hoover@osumc.edu</Email><Name>Amy Hoover, LPN</Name><Phone>614-293-0390</Phone></Contact><Contact type="Facility contact backup"><Email>samir.zaparde@osumc.edu</Email><Name>Samir Zaparde, MD</Name><Phone>614-313-4921</Phone></Contact><Contact type="Facility investigator"><Name>Sashwati Roy, Ph.D`</Name></Contact></Contacts></Site><Site><Name>The Ohio State University Hospital East</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43203</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>amy.hoover@osumc.edu</Email><Name>Amy Hoover, LPN</Name><Phone>614-293-0390</Phone></Contact><Contact type="Facility contact backup"><Email>samir.zaparde@osumc.edu</Email><Name>Samir Zaparde, BS</Name><Phone>614-313-4921</Phone></Contact><Contact type="Facility investigator"><Name>Sashwati Roy, Ph.D</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="7610">Subjects with Diabetic Complications</PatientSegment><SubSegments><SubSegment id="7611">Subjects with diabetic foot</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7645">Subjects with Moderate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7646">Subjects with Good Glycemic Control</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="102">Subjects with Good Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="110">Subjects with Diabetic Complications</PatientSegment><SubSegments><SubSegment id="111">Subjects with diabetic foot</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="145">Subjects with Moderate Glycemic Control</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Diabetic complication</Disease><PatientSegments><PatientSegment><PatientSegment id="8456">Subjects with Diabetic Foot Diseases</PatientSegment><SubSegments><SubSegment id="8457">Subjects with diabetic foot ulcers</SubSegment><SubSegment id="8458">Subjects with diabetic foot infections</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03271580</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Diabetic complication" id="11216"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Diabetic complication" id="11391"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Diabetic complication" id="11405">Hematology tests</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Diabetic complication" id="11216"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Diabetic complication" id="11391"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Diabetic complication" id="11405">Hematology tests</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Diabetic complication" id="45404"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Diabetic complication" id="11439"><Endpoint>Assessment of Wound Healing</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="639"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1061">Study specific protocol requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="683"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Diabetic complication" id="6952"><Criterion>Subjects with Diabetes Mellitus</Criterion></Inclusion><Inclusion disease="Diabetic complication" id="7007"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="Diabetic complication" id="7034"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="7067">Study specific protocol requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16345"><Criterion>Subjects scheduled to receive disease specific therapy</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16356"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16360">Ability/willingness to perform required test/procedures</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33510"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="606">Subjects with Good Glycemic Control</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="901">Subjects with Moderate Glycemic Control</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Diabetic complication" id="33670"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33671"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion></Inclusion><Inclusion disease="Diabetic complication" id="34451"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="7040">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="34466"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16363">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="34467"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="906">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Diabetic complication" id="34810"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="7035">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="34875"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16358">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion><SubCriterion disease="Insulin dependent diabetes" id="16384">Subjects willing/able to complete follow up period</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="34922"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1042">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Diabetic complication" id="35047"><Criterion>Subjects with Diabetic Complications</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="6974">Subjects with Diabetic Foot</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35051"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16355">Subjects with Good Glycemic Control</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Diabetic complication" id="35052"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="7030">Subjects with Moderate Glycemic Control</SubCriterion><SubCriterion disease="Diabetic complication" id="7031">Subjects with Good Glycemic Control</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35101"><Criterion>Subjects with Diabetes Mellitus</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="35698"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1045">Subjects with diabetic foot</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35707"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16316">Subjects with diabetic foot</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="899"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5621">Immunocompromised conditions</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="963"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5074"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5076">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5078"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Diabetic complication" id="8549"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion></Exclusion><Exclusion disease="Diabetic complication" id="8565"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8567">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diabetic complication" id="8587"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8593">Immunocompromised conditions</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diabetic complication" id="8609"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Diabetic complication" id="8637"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13793"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13812"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13814">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13835"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13850"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13872"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="25726"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1061">Pregnant women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="25727"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13905">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diabetic complication" id="25743"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8686">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diabetic complication" id="26283"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8604">Subjects with history/scheduled to undergo organ transplantation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="26284"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="982">Subjects with history/scheduled to undergo organ transplantation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="27046"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13844">Subjects with history/scheduled to undergo organ transplantation</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-02-05T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-06-12T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-09-06T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="331474"><TitleDisplay>A retrospective cohort study on the evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="1076">Thrombosis</Indication></Indications><BiomarkerNames><BiomarkerName id="30714" role="Therapeutic effect marker" type="Proteomic">Anti-factor Xa antibodies</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tinzaparin sodium</Name><Drug id="6295">tinzaparin sodium</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6295">tinzaparin sodium</Drug><IndicationsPioneer/><Companies><Company><Company id="17774">LEO Pharma A/S</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6295" type="Drug"><TargetEntity id="135202" type="siDrug">Tinzaparin sodium</TargetEntity></SourceEntity><SourceEntity id="17774" type="Company"><TargetEntity id="4297354408" type="organizationId">Leo Pharma A/S</TargetEntity></SourceEntity><SourceEntity id="1076" type="ciIndication"><TargetEntity id="10043607" type="MEDDRA"/><TargetEntity id="D013927" type="MeSH"/><TargetEntity id="304" type="siCondition"/></SourceEntity><SourceEntity id="120" type="Action"><TargetEntity id="679" type="Mechanism">Coagulation Factor Xa Inhibitors</TargetEntity><TargetEntity id="6421" type="Mechanism">Anti-Factor Xa</TargetEntity></SourceEntity><SourceEntity id="75" type="Action"><TargetEntity id="3180" type="Mechanism">Antithrombin III Activators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="17774">LEO Pharma A/S</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="120">Factor Xa antagonist</Action><Action id="1741">Low molecular weight heparin</Action><Action id="75">Antithrombin III</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="659">Coagulation inhibitor</Class><Class id="74">Antioxidant agent</Class></Class><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>79</PatientCountEnrollment><PatientCountEvaluable>57</PatientCountEvaluable><DateChangeLast>2018-03-12T04:26:33Z</DateChangeLast><DateAdded>2018-03-08T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Children aged 0 to&amp;lt; 16 years treated for thrombosis &lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>To evaluate tinzaparin dosing</Description></Measure><Measure><Description>Anti-activated factor X (FXa) levels</Description></Measure><Measure><Description>Patient outcomes</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this retrospective cohort study was to investigate the use of &lt;ulink linkType="Drug" linkID="6295"&gt;tinzaparin&lt;/ulink&gt; for the treatment of childhood thrombosis and to evaluate the age-dependent dosing recommendations and define outcomes in terms of efficacy and safety [&lt;ulink linkType="Reference" linkID="2011176"&gt;2011176&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2018, results were published. It was observed that younger children required higher doses to reach a therapeutic level and the therapeutic dose requirement varied within age groups supporting the use of anti-FXa monitoring. There were 13 (16%) bleeding episodes (two major; seven clinically relevant but non-major; and four minor) over a median follow-up of 35 months and there were two (3%) recurrent episodes of thrombosis. Median duration of treatment was 3 months and the majority (86%) of children remained on tinzaparin for the duration of their anticoagulant therapy [&lt;ulink linkType="Reference" linkID="2011176"&gt;2011176&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Children aged 0 to &amp;lt; 16 years who were treated with once-daily tinzaparin at a large teaching hospital in the UK between 2008 and 2015 were included and observed [&lt;ulink linkType="Reference" linkID="2011176"&gt;2011176&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-03-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="332230"><TitleDisplay>Bariatric Surgery and Pharmacokinetics of Escitalopram</TitleDisplay><TitleOfficial>Bariatric Surgery and Pharmacokinetics Escitalopram: BAR-MEDS Escitalopram</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03460379</Identifier><Identifier type="Organisational Study">2016/1145K</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>citalopram hydrobromide</Name><Drug id="2822">citalopram hydrobromide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>escitalopram</Name><Drug id="17518">escitalopram</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>gastric bypass surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sleeve gastrectomy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17518">escitalopram</Drug><IndicationsPioneer/><Companies><Company><Company id="1039589">St Olavs Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1074753">Alesund Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1097076">Namsos Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1161331">Volvat Medical Center Stokkan</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="28980">Norwegian University of Science and Technology (NTNU)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2822">citalopram hydrobromide</Drug><IndicationsPioneer><Indication id="238">Obesity</Indication></IndicationsPioneer><Companies><Company><Company id="1039589">St Olavs Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1074753">Alesund Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1097076">Namsos Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1161331">Volvat Medical Center Stokkan</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="28980">Norwegian University of Science and Technology (NTNU)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="17518" type="Drug"><TargetEntity id="157449" type="siDrug">Escitalopram oxalate</TargetEntity></SourceEntity><SourceEntity id="2822" type="Drug"><TargetEntity id="90241" type="siDrug">Citalopram hydrobromide</TargetEntity></SourceEntity><SourceEntity id="1039589" type="Company"><TargetEntity id="5035542990" type="organizationId">St Olavs Hospital</TargetEntity></SourceEntity><SourceEntity id="1074753" type="Company"><TargetEntity id="5037940986" type="organizationId">Alesund sjukehus</TargetEntity></SourceEntity><SourceEntity id="1097076" type="Company"><TargetEntity id="5042944562" type="organizationId">Sykehuset Namsos</TargetEntity></SourceEntity><SourceEntity id="1161331" type="Company"><TargetEntity id="5062368930" type="organizationId">Volvat Stokkan</TargetEntity></SourceEntity><SourceEntity id="28980" type="Company"><TargetEntity id="4298462378" type="organizationId">Norwegian University of Science and Technology</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="28980">Norwegian University of Science and Technology (NTNU)</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1039589">St Olavs Hospital</Company><Company id="1074753">Alesund Hospital</Company><Company id="1097076">Namsos Hospital</Company><Company id="1161331">Volvat Medical Center Stokkan</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="2941">Antidepressant</Class><Class id="2942">Anxiolytic</Class><Class id="3">5-HT uptake inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="630">Stereochemistry</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>12</PatientCountEnrollment><DateStart>2016-11-02T00:00:00Z</DateStart><DateEnd type="estimated">2026-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-03-16T22:01:01Z</DateChangeLast><DateAdded>2018-03-14T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>magnus.strommen@stolav.no</Email><Name>Magnus Strømmen, MSc</Name><Phone>0047 72829970</Phone></Contact><Contact type="Scientific contact"><Affiliation>St. Olavs University Hospital</Affiliation><Name>Magnus Strømmen, MSc</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway&lt;/li&gt;&lt;li&gt;Being a Norwegian citizen&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Having previously undergone resections in the GI-tract&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Escitalopram concentration in blood serum (area under curve [AUC])</Description><Timeframe>From baseline to one year postoperatively</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In this study the pharmacokinetic effects of bariatric surgery on      &lt;ulink linkType="Drug" linkID="17518"&gt;escitalopram&lt;/ulink&gt; will be investigated.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients referred for bariatric surgery (gastric bypass or sleeve gastrectomy) will be tested for their normal prescription escitalopram or &lt;ulink linkType="Drug" linkID="2822"&gt;citalopram&lt;/ulink&gt; medication and observed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Norway"><Sites><Site><Name>St. Olavs University Hospital</Name><Address1>Trondheim</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Magnus Strømmen, MSc</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7750">Subjects Scheduled for Bariatric Surgery</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03460379</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20671"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20675">Area under concentration curve (AUC)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19743"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19744">Subjects with history/scheduled for bariatric surgery or gastric bypass surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19790"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15392">Subjects with history of/planned surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2026-10-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-03-04T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-03-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="339848"><TitleDisplay>A randomized controlled trial of modified tension band reducing flexion restriction of knee joint due to the rotation of K-wire in the treatment of patellar fracture</TitleDisplay><TitleOfficial>A randomized controlled trial of modified tension band reducing flexion restriction of knee joint due to the rotation of K-wire in the treatment of patellar fracture</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1800016105</Identifier></Identifiers><Indications><Indication id="3895">Knee fracture</Indication></Indications><BiomarkerNames><BiomarkerName id="46522" role="Therapeutic effect marker" type="Physiological">Knee motion</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>modified patallar tension band</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>traditional patallar tension band</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1046054" type="Company"><TargetEntity id="5035545687" type="organizationId">Beijing Hospital of Ministry of Health</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1046054">Beijing Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>148</PatientCountEnrollment><DateStart>2018-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2023-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-05-24T02:52:47Z</DateChangeLast><DateAdded>2018-05-22T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Beijing Hospital</Affiliation><Email>sfp19881110@126.com</Email><Name>Sun Fengpo</Name><Phone>+86 18201088091</Phone></Contact><Contact type="Scientific contact"><Affiliation>Beijing Hospital</Affiliation><Email>wenliangyuan1964@126.com</Email><Name>Wen Liangyuan</Name><Phone>+86 13911901100</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Displaced patellar fracture (separation &gt; 3 mm or the step height of fracture &gt; 2 mm)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;The general status is bad and can't tolerate the operation&lt;/li&gt;&lt;li&gt;Disagree to join the research&lt;/li&gt;&lt;li&gt;The capacity for action is bad before pataller fracture or can't move&lt;/li&gt;&lt;li&gt;Pathological fracture&lt;/li&gt;&lt;li&gt;Can't be followed up after the operation and can't do the rehabilitation and take drugs&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Range of knee joint flextion</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim is to compare the impact to the rotation restrict of knee joint between modified tension band and traditional tension band in the treatment of patellar fracture.  &lt;/para&gt;&lt;para&gt;s&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive  modified patallar tension band or traditional patallar tension band. Each arm will have n = 74.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Beijing Hospital</Name><Address1>Dongcheng</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18266">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1800016105</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other musculoskeletal disease" id="42991"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other musculoskeletal disease" id="43701"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other musculoskeletal disease" id="32742"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Other musculoskeletal disease" id="35079"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other musculoskeletal disease" id="24023"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24089"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="342843"><TitleDisplay>Psychoeducational Approach for Inpatients With Reccurent Polydipsia</TitleDisplay><TitleOfficial>Effect of Psychoeducational Appoach on the Prevention of Water Intoxication for Inpatients With Reccurent Polydipsia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000032142</Identifier></Identifiers><Indications><Indication id="2952">Water intoxication</Indication><Indication id="3039">Polydipsia</Indication></Indications><BiomarkerNames><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>psychoeducation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1116461" type="Company"><TargetEntity id="5047643506" type="organizationId">Sawa Hospital</TargetEntity></SourceEntity><SourceEntity id="2952" type="ciIndication"><TargetEntity id="10047837" type="MEDDRA"/><TargetEntity id="D014869" type="MeSH"/></SourceEntity><SourceEntity id="3039" type="ciIndication"><TargetEntity id="R63.1" type="ICD10"/><TargetEntity id="10036067" type="MEDDRA"/><TargetEntity id="D059606" type="MeSH"/><TargetEntity id="-545676310" type="omicsDisease"/><TargetEntity id="3939" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1116461">Sawa Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>3</PatientCountEnrollment><DateStart>2018-06-14T00:00:00Z</DateStart><DateChangeLast>2019-03-11T11:12:48Z</DateChangeLast><DateAdded>2018-06-15T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Sawa Hospital ; Nursing Division</Affiliation><Email>nur@hokuto-kai.com</Email><Name>Katsumi Matsumoto,BSN</Name><Phone>06-6865-1211</Phone></Contact><Contact type="Scientific contact"><Affiliation>Sawa Hospital ; Nursing Division</Affiliation><Email>nur@hokuto-kai.com</Email><Name>Katsumi Matsumoto,BSN</Name><Phone>06-6865-1211</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Inpatients at high risk for water intoxication due to reccurent polydipsia&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Normalized diurnal weight gain</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to  improve the behavioral disorder.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive psychoeducation (behavioral therapy).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Sawa Hospital; 	Nursing Division</Name><Address1>Toyonaka</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gastrointestinal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18219">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16000">Subjects with Nutritional Disorder</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000032142</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other gastrointestinal disease" id="46282"><Endpoint>Anthropometric Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other gastrointestinal disease" id="32953"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="35070"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-06-15T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="removed"><Date>2019-03-16T00:00:00Z</Date><Reason id="314">Eligibility Criteria removed</Reason></Change></ChangeHistory></Trial><Trial id="362917"><TitleDisplay>Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)</TitleDisplay><TitleOfficial>Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03768765</Identifier><Identifier type="Organisational Study">143049</Identifier></Identifiers><Indications><Indication id="1241">Prostate hyperplasia</Indication></Indications><BiomarkerNames><BiomarkerName id="10930" role="Therapeutic effect marker" type="Physiological">Post-void residual urine</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Holmium Laser Prostate Surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="27708" type="Company"><TargetEntity id="5035554581" type="organizationId">University of Kansas Medical Center</TargetEntity></SourceEntity><SourceEntity id="1241" type="ciIndication"><TargetEntity id="10051482" type="MEDDRA"/><TargetEntity id="D011470" type="MeSH"/><TargetEntity id="-1410482198" type="omicsDisease"/><TargetEntity id="362" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="27708">University of Kansas Medical Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>150</PatientCountEnrollment><DateStart>2018-11-15T00:00:00Z</DateStart><DateEnd type="estimated">2022-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-12-19T11:48:25Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>University of Kansas Medical Center</Affiliation><Name>Kerri Barnes</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must be 18 years of age or older&lt;/li&gt;&lt;li&gt;Patients must present to clinic with a diagnosis of benign prostatic hyperplasia with lower urinary tract symptoms&lt;/li&gt;&lt;li&gt;Patients must be scheduled to undergo a holmium laser prostate surgery (enucleation or ablation)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who are under 18 years of age are not eligible&lt;/li&gt;&lt;li&gt;Patients who have a diagnosis of bladder cancer are not eligible&lt;/li&gt;&lt;li&gt;Patient who have a diagnosis of prostate cancer are not eligible&lt;/li&gt;&lt;li&gt;Patients with an elevated prostate-specific antigen (PSA) suggesting prostate cancer are not eligible unless patient has prior negative prostate biopsy&lt;/li&gt;&lt;li&gt;Patients who have acute prostatitis, a prostate abscess, or neurogenic bladder are not eligible&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Bladder Function: the primary objective is to determine if patients who undergo holmium laser surgery prior to being placed on long term medication for benign prostatic hyperplasia (BPH) have a greater improvement in their bladder function, as measured by urodynamics, when compared to patients who undergo holmium laser surgery after being placed on long term medication for BPH</Description><Timeframe>Six Months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Complete Emptying: the secondary objectives are to determine if patients who undergo holmium laser surgery prior to long term medication for benign prostatic hyperplasia have great improvement in complete emptying of their bladder, as measured by post void residual volume (PVR), when compared to patients who under holmium laser surgery after having received long term medication</Description><Timeframe>Six Months</Timeframe></Measure><Measure><Description>Lower Urinary Tract Symptoms: the secondary objectives are to determine if patients who undergo holmium laser surgery prior to long term medication for benign prostatic hyperplasia have great improvement in regards to their lower urinary tract symptoms, as measured by the American Urology Association (AUA) symptom score, when compared to patients who under holmium laser surgery after having received long term medication. The AUA symptom score is a measure of lower urinary tract symptoms and is scored on a scale of 0-25, with a score in the range of 0-8 indicating mild symptoms, 9-19 indicating moderate symptoms, and a score in 20-35 range indicating severe symptoms</Description><Timeframe>Six Months</Timeframe></Measure><Measure><Description>Quality of Life: the secondary objectives are to determine if patients who undergo holmium laser surgery prior to long term medication for benign prostatic hyperplasia (BPH) have a greater improvement in their quality of life, as measured by questionnaires, when compared to patients who under holmium laser surgery after having received long term medication</Description><Timeframe>Six Months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim is to determine if the prior prolonged use of medication, as a treatment for benign prostatic      hyperplasia, reduces the efficacy of Holmium laser enucleation of the prostate (HoLEP) for      patients with benign prostatic hyperplasia (BPH).The goal of this clinical trial is to investigate if a prolonged period of medication is associated with the effectiveness of holmium laser surgery. By grouping patients based on medication treatment time, the goal is to determine if their responses are different and clinically significant, in order to better inform standard of care practices for those with BPH.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study is divided into two experimental arms:&lt;br/&gt;Arm 1: patients who have been on medication for over a year(Long Term Medication Usage)  for benign prostatic hyperplasia (BPH) will undergo standard of care holmium laser prostate surgery.&lt;br/&gt;Arm 2: Patients who have been on medication for under a year(Short Term Medication Usage) for benign prostatic hyperplasia (BPH)&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of Kansas Health System</Name><Address1>Kansas City</Address1><Address2>Kansas</Address2><Address3>66160</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>adahlgren@kumc.edu</Email><Name>Alexandra Dahlgren</Name><Phone>913-574-0847</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate hyperplasia</Disease><PatientSegments><PatientSegment><PatientSegment id="11507">Subjets with Benign Prostatic Hypertrophy/Hyperplasia(BPH)</PatientSegment><SubSegments><SubSegment id="11514">Subjects with lower urinary tract symptoms(LUTS)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11526">Subjects with Surgical Treatment</PatientSegment><SubSegments><SubSegment id="11530">Subjects with laser surgery</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03768765</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate hyperplasia" id="22626"><Endpoint>Assessment of Urodynamics</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Prostate hyperplasia" id="22656"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="22659">Other laboratory assessment</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate hyperplasia" id="22610"><Endpoint>Subjective Assessment of BPH Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate hyperplasia" id="22613"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="22622">American Urologic Association Sympton Score(AUASS)</SubEndpoint><SubEndpoint disease="Prostate hyperplasia" id="22624">Quality of life(QOL)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate hyperplasia" id="22626"><Endpoint>Assessment of Urodynamics</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="22627">Assessment of  post void residual (PVR) urine volume</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate hyperplasia" id="20360"><Criterion>Subjets with Benign Prostatic Hypertrophy/Hyperplasia(BPH)</Criterion></Inclusion><Inclusion disease="Prostate hyperplasia" id="20371"><Criterion>Subjects with lower urinary tract symptoms(LUTS)</Criterion></Inclusion><Inclusion disease="Prostate hyperplasia" id="20383"><Criterion>Subjects with Surgical Treatment</Criterion><SubCriteria><SubCriterion disease="Prostate hyperplasia" id="20387">Subjects with laser surgery</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate hyperplasia" id="17871"><Criterion>Subjects co-morbid with genitourinary disorders</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17872"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate hyperplasia" id="17873">Subjects co-morbid with prostate cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate hyperplasia" id="27695"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="27775"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-12-03T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="383034"><TitleDisplay>Effects of Inspiratory Muscle Training in Frail elderly people on Cough Strength</TitleDisplay><TitleOfficial>Effects of Inspiratory Muscle Training in Frail elderly people on Cough Strength</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000036924</Identifier></Identifiers><Indications><Indication id="668">Muscle weakness</Indication></Indications><BiomarkerNames><BiomarkerName id="1912" role="Therapeutic effect marker" type="Physiological">Forced Vital Capacity</BiomarkerName><BiomarkerName id="2713" role="Therapeutic effect marker" type="Physiological">Forced expiratory volume</BiomarkerName><BiomarkerName id="12110" role="Therapeutic effect marker" type="Physiological">Maximal inspiratory mouth pressure</BiomarkerName><BiomarkerName id="12111" role="Therapeutic effect marker" type="Physiological">Maximal expiratory mouth pressure</BiomarkerName><BiomarkerName id="17876" role="Therapeutic effect marker" type="Physiological">Peak cough flow</BiomarkerName><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName><BiomarkerName id="40656" role="Therapeutic effect marker" type="Physiological">Knee extension strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>inspiratory muscle training</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>regular rehabilitation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>regular rehabilitation</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="31540" type="Company"><TargetEntity id="4296671462" type="organizationId">Nagasaki University</TargetEntity></SourceEntity><SourceEntity id="668" type="ciIndication"><TargetEntity id="M62.81" type="ICD10"/><TargetEntity id="10028372" type="MEDDRA"/><TargetEntity id="D018908" type="MeSH"/><TargetEntity id="-880109541" type="omicsDisease"/><TargetEntity id="157" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="31540">Nagasaki University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2019-06-02T00:00:00Z</DateStart><DateChangeLast>2019-06-08T03:03:02Z</DateChangeLast><DateAdded>2019-06-04T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Nagasaki University Graduate School of Biomedical Sciences ; Department of Physical Therapy Science </Affiliation><Email>da1110kj@gmail.com</Email><Name>Morishita Tatsuya</Name><Phone>095-819-7963</Phone></Contact><Contact type="Scientific contact"><Affiliation>Nagasaki University Graduate School of Biomedical Sciences ; Department of Physical Therapy Science </Affiliation><Name>ryo kozu</Name></Contact><Contact type="Public contact"><Affiliation>Nagasaki University Graduate School of Biomedical Sciences ; Department of Physical Therapy Science </Affiliation><Email>da1110kj@gmail.com</Email><Name>Tatsuya Morishita</Name><Phone>095-819-7963</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Frail elderly people based on Fried's CHS criteria&lt;/li&gt;&lt;li&gt;Age &gt;/= 65 years&lt;/li&gt;&lt;li&gt;Person who conducted research explanation and obtained written consent for exercise&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;In the case where the attending physician or research director decides that it is inappropriate&lt;/li&gt;&lt;li&gt;Cases judged to be difficult to conduct IMT&lt;/li&gt;&lt;li&gt;Cases where equipment can not be used properly&lt;/li&gt;&lt;li&gt;Cases that can not be coughed&lt;/li&gt;&lt;li&gt;Cases where 8week intervention is impossible&lt;/li&gt;&lt;li&gt;Cases scheduled for surgery within the study period&lt;/li&gt;&lt;li&gt;Patients who have difficulty walking by themselves&lt;/li&gt;&lt;li&gt;Cases with a history of pneumothorax&lt;/li&gt;&lt;li&gt;Cases that have developed cancer&lt;/li&gt;&lt;li&gt;A case that exacerbated comorbidity within 4 weeks&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cough peak flow (CPF)</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Maximum inspiratory mouth pressure (PImax), maximum expiratory mouth pressure (PEmax), FVC, FEV1, repetitive salvia swallowing test (RSST), Tongue pressure, Short Physical Performance Battery (SPPB), Grip strength, Isometric Knee Extension Force, Barthel Index</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is the effect of inspiratory muscle training for frail elderly people on improvement of cough strength.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consist of two groups:&lt;br/&gt;Group 1: in addition to regular rehabilitation, the exercise group will perform inspiratory muscle training for at least 3 days a week for 8 weeks. Inspiratory muscle training is performed twice a day at 30% of PImax 30 times a day (Reassess the load intensity after 4 weeks of intervention). &lt;br/&gt;Group 2: the control group will perform regular rehabilitation only for 8 weeks. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Nagasaki University Graduate School of Biomedical Sciences ; Department of Physical Therapy Science</Name><Address1>Nagasaki Prefecture</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000036924</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-06-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="94102"><TitleDisplay>WBV and Acute Lateral Ankle Sprain</TitleDisplay><TitleOfficial>The Effect of Whole Body Vibration and Acute Unilateral Unstable Lateral Ankle Sprain - A Biphasic, Randomized, Controlled Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">315-12</Identifier><Identifier type="NCT">NCT01702597</Identifier><Identifier type="Secondary Organisational">MMW-Stiftung</Identifier><Identifier type="Trial Acronym">WBV and ALAS</Identifier></Identifiers><Indications><Indication id="2439">Arthralgia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Galileo Med M Plus</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Physiotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1031255" type="Company"><TargetEntity id="5035525131" type="organizationId">Innsbruck Medical University</TargetEntity></SourceEntity><SourceEntity id="22137" type="Company"><TargetEntity id="5001197150" type="organizationId">Ludwig Maximilians Universitaet Muenchen</TargetEntity></SourceEntity><SourceEntity id="2439" type="ciIndication"><TargetEntity id="10003239" type="MEDDRA"/><TargetEntity id="D018771" type="MeSH"/><TargetEntity id="-792328721" type="omicsDisease"/><TargetEntity id="719" type="siCondition"/><TargetEntity id="2592" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="22137">Ludwig-Maximilians University of Munich</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1031255">Medizinische Universität Innsbruck</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2012-10-31T00:00:00Z</DateStart><DateEnd type="estimated">2014-04-30T00:00:00Z</DateEnd><DateChangeLast>2018-06-19T03:34:28Z</DateChangeLast><DateAdded>2012-10-11T13:31:44Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Ludwig-Maximilians - University of Munich</Affiliation><Name>Matthias Schieker, Prof.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Acute, unilateral, unstable, inversion ankle sprain (grade II, III)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Conditions affecting the neuromuscular- or musculoskeletal system&lt;/li&gt;&lt;li&gt;Previous surgical interventions to the foot, ankle, knee or hip; known FAI, CAI&lt;/li&gt;&lt;li&gt;Conditions possibly affecting balance&lt;/li&gt;&lt;li&gt;Cardiovascular disease including thrombosis&lt;/li&gt;&lt;li&gt;Respiratory diseases&lt;/li&gt;&lt;li&gt;Abdominal diseases (including gallstones)&lt;/li&gt;&lt;li&gt;Urological diseases (including kidney- and bladder stones)&lt;/li&gt;&lt;li&gt;Gynaecological diseases and  intrauterine devices&lt;/li&gt;&lt;li&gt;Neurological diseases including epilepsia within the last two years&lt;/li&gt;&lt;li&gt;Acute injuries to the head&lt;/li&gt;&lt;li&gt;Patient is not available for follow up visits&lt;/li&gt;&lt;li&gt;Patient unable to give informed consent&lt;/li&gt;&lt;li&gt;Patient suspected to be non-compliant&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Postural control: sway index measured via the Leonardo Mechanograph GRFP (16 bit, 800 Hz; NOVOTEC Medical GmbH, Germany)</Description><Timeframe>6 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Subjective instability: patient recorded giving-way symptoms or recurrence</Description><Timeframe>One year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this bicentric, biphasic, randomized, controlled study is to compare the      current gold standard functional treatment to functional treatment plus WBV in patients with      acute unilateral unstable inversion ankle sprains over a period of 12 months.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized by envelope drawing. Patients in arm 1 will receive supervised physical therapy using a whole body vibration device (Galileo Med M Plus, Novotec, Pforzheim, Germany) twice a week, 30 min per session, for 6 weeks and patients in arm 2 will receive the current gold standard treatment protocol under supervised physical therapy, twice a week, 30 min per session, for 6 weeks. All patients will be allowed early mobilization and pain-depending weight bearing, limited functional immobilization by orthesis, PRICE, NSARDs as well as home and supervised physiotherapy. Supervised physical therapy will take place twice a week, 30 min per session, for 6 weeks, following a standardized intervention protocol. During supervised physical therapy, the intervention group will perform similar exercises on a side-alternating sinusoidal vibration platform as the control group. A total of two-time dependent primary outcome parameters will be assessed. Short-term outcome after 6 weeks will be postural control quantified by the sway index. Mid-term outcome after one year will be assessed by subjective instability, defined by the presence of giving-way attacks. Secondary outcome parameters include return to pre-injury level of activities, residual pain, recurrence, objective instability, energy/coordination, Foot and Ankle Disability Index and EQ 5D.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01702597</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Anticipated">2013-04-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-10-03T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-10-11T13:31:44Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>